Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging.
Breast cancer
axillary dissection
level I axillary dissection
neoadjuvant chemotherapy
sentinel lymph node biopsy
Journal
Turkish journal of surgery
ISSN: 2564-6850
Titre abrégé: Turk J Surg
Pays: Turkey
ID NLM: 101704837
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
09
12
2022
accepted:
29
01
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
The purpose of the study was to investigate the oncological sufficiency of level I axillary dissection for adequate histological nodal staging (ypN) in patients with breast cancer and tumor-involved sentinel lymph node (SLN) after neoadjuvant chemotherapy (NAC). A prospective multicentre pilot study took place from 01.01.2018 to 30.11.2020 in three mammary centres in the Czech Republic in patients with breast cancer after NAC (NCT03556397). Patients in the cohort with positive histological frozen section of SLN were indicated to separate axillary dissection of levels I and II. Sixty-one patients with breast cancer after NAC were included in the study according to inclusion and exclusion criteria. Twelve patients with breast cancer and tumour involved SLN after NAC were further included in the analysis. Two (16.7%) patients had positive non-sentinel lymph nodes in level I only, one (8.3%) patient had positive lymph nodes in level II only, and seven (58.3%) patients had positive lymph nodes in both levels. Level I axillary dissection in a patient with tumour involved SLN after NAC would have resulted in understaging in five (41.7%) patients, mostly ypN1 instead of ypN2. According to our pilot result, level I axillary dissection is not sufficient in terms of adequate histological nodal staging in breast cancer patients after NAC, and level II axillary dissection should not be omitted.
Identifiants
pubmed: 37275927
doi: 10.47717/turkjsurg.2023.5984
pmc: PMC10234716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-6Informations de copyright
Copyright © 2023, Turkish Surgical Society.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no conflicts of interest to declare.
Références
Eur J Surg Oncol. 2017 Apr;43(4):672-679
pubmed: 28139362
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1030-1039
pubmed: 32585337
JAMA Oncol. 2017 Apr 01;3(4):549-555
pubmed: 27918753
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810544
Br J Surg. 2021 May 27;108(5):583-589
pubmed: 34043772
Eur J Surg Oncol. 1988 Oct;14(5):407-12
pubmed: 3181444
Breast. 2019 Nov;48 Suppl 1:S53-S56
pubmed: 31839161
Breast. 2021 Oct;59:256-269
pubmed: 34325383
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Clin Oncol. 2016 Apr 1;34(10):1072-8
pubmed: 26811528
Cancers (Basel). 2021 Jan 06;13(2):
pubmed: 33418983
JAMA Surg. 2019 Sep 1;154(9):800-809
pubmed: 31314062
Ann Surg Oncol. 2021 Feb;28(2):930-940
pubmed: 32712895
Sci Rep. 2021 Apr 27;11(1):9056
pubmed: 33907236
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Breast J. 2020 Dec 2;:
pubmed: 33289332